Reading AXSM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AXSM free→Reading AXSM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AXSM free→QuarterlyIQ Insights · AXSM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Axsome Therapeutics, Inc. (the “Company”) approved the adoption of the Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan (the “Severance Plan”), effective on June 5, 2026, which provides for severance benefits to certain key employees, inc…
Other Events. On June 3, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release entitled “Axsome Therapeutics Announces Settlement Resolving All SUNOSI ® (solriamfetol) Patent Litigation.” The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.